H.R. 1717 · 118th Congress · Commerce

Interagency Patent Coordination and Improvement Act of 2023

Died in committee1.4k words Introduced Mar 22, 2023 · Latest action Mar 22, 2023

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedMar 22, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

Congressional Research Service · summary of “Introduced in House” version · Mar 22, 2023

Who lobbies on it

8 organizations · 45 filings · Q1 2023–Q4 2024

See which of this bill’s sponsors and cosponsors got money from the lobbying organizations’ PACs → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 8 of 8 quarters
    “H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents…”

    $31.0M lobbying spend in 2024, all issuesQ4 2024 filing

  2. Biotechnology Innovation Organization 8 of 8 quarters
    “…H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128: A bill to establish…”

    $6.7M lobbying spend in 2024, all issuesQ4 2024 filing

  3. American Intellectual Property Law Association (aipla) 8 of 8 quarters
    “…H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United…”

    $10K lobbying spend in 2024, all issuesQ4 2024 filing

5 more organizations, every filingPROUpgrade

Organizations that named H.R. 1717 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Mar 22, 2023Referred to the House Committee on the Judiciary.
  2. Mar 22, 2023Introduced in House